Egetis Therapeutics AB(0ABW)
SEK --+0.00%
Reward45Moderate
Risk46Moderate
25%Data
0ABW
+0.0 · +0.00%
SEK · LSE
Egetis Therapeutics AB |
Value Trap
Market Cap:
Reward Rating
45
Moderate
Reward Assessment
25% data coverage
Bottom 25% of stocksView factors
Risk Rating
46
Moderate
Risk Assessment
50% data coverage
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0ABW to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for 0ABW, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Egetis Therapeutics AB?

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.

0ABW · Verdict

Moderate reward · moderate risk

0ABW's standout is volatility, while growth remains the main concern.

Based on 38% data coverage

0ABW · Verdict

What’s working & what to watch

Strengths 1

  • Volatility65/100

    Above average

Watchouts 1

  • Growth34/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Egetis Therapeutics AB?

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
IndustryN/A
Market CapN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.779
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.